Company Overview - Klotho Neurosciences, Inc. is a U.S.-based biotechnology company focused on developing cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's [1][5] - The company utilizes a patented form of the "anti-aging" human Klotho gene (S-KL) and a novel delivery system (s-KL/AAV.myo) to enhance treatment options for these diseases [5] Leadership Appointment - Riad El-Dada, former US President of Merck, has been appointed to the Board of Directors of Klotho Neurosciences [1][4] - El-Dada brings decades of leadership experience in the pharmaceutical industry, having managed over $12 billion in revenue during his tenure at Merck [2][3] Strategic Importance - El-Dada's expertise in pharmaceutical innovation, strategic leadership, and operational excellence is expected to be invaluable for Klotho Neurosciences as it advances its mission [4] - His background includes negotiating key development and commercialization deals, which will support Klotho's efforts in developing its Klotho gene therapy aimed at neurodegenerative diseases [3][4] Company Vision - Klotho Neurosciences aims to transform the treatment landscape for diseases such as ALS, Alzheimer's, and Parkinson's through innovative therapies [4] - The company is committed to driving value for shareholders while providing hope to millions of patients and families worldwide [4]
Former Merck USA President Joins Klotho Neurosciences' Board of Directors